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Summary Type I collagen is the main collagen type found in mineralised bone. Specific immunoassays for
PICP (carboxyterminal propeptide of type I procollagen) and ICTP (cross-linked carboxyterminal telopeptide
region of type I collagen) allow simultaneous assessment of the synthesis and degradation of type I collagen in
serum samples, respectively. Our aim was to find out whether these metabolites of type I collagen are useful
markers for following bone turnover and evaluating treatment response in multiple myeloma, which is a good
model disease of excessive osteolysis. Fifteen consecutive patients were studied before and throughout their
treatment. Samples for serum PICP and ICTP were collected before starting each treatment course of
melphalan and prednisolon. Response to treatment was evaluated by following the changes in M protein and
bone roentgenograms. The disease was progressing in four and regressive in 11 patients, but in four of these a
recurrence occurred. In nonresponders the ICTP concentration was permanently elevated despite treatment. In
responders both increased or normal levels of ICTP were initially observed, but they returned to or remained
in the reference interval during treatment. The ICTP concentration increased upon recurring disease. There
was a strong correlation between the extent of bone lesions and ICTP. There was no correlation between ICTP
and PICP, the latter mainly remaining within the reference range, a finding that suggests no change in bone
formation. ICTP was a significant predictor for survival in this patient group (P< 0.05). We conclude that
ICTP is a specific and sensitive marker for bone resorption. Simultaneous use of serum ICTP and PICP offers
an additional and easy means to follow bone turnover and evaluate the response to therapy in multiple
myeloma.
Skeletal disease is a major cause of morbidity in myeloma.
Bone pain and fractures result from loss of bone. Bone
resorption is increased due to osteoclast activating factors,
which are elaborated by myeloma cells. One of the most
potent factors is lymphotoxin (Garrett et al., 1987).
The mainstay of long-term management in multiple mye-
loma is adequate chemotherapy. The response to treatment
has been evaluated by measuring the M proteins. A decrease
in or disappearance of the M proteins indicates reduction of
tumour mass in the bone marrow, but it does not reflect
healing of the skeletal disease (Durie & Salmon, 1975).
Therefore measurements of bone metabolism have been used
(Kraenzlin et al., 1989).
Until recently the only assays available for bone turnover
were serum alkaline phosphatase for monitoring bone forma-
tion and urinary calcium and hydroxyproline for monitoring
bone resorption. None of these is specific for bone and all
have been proven insensitive and unreliable. Nowadays more
specific assays, namely osteocalcin for the assessment of bone
formation and pyridinoline cross-links for the assessment of
bone resorption, have been developed (Kraenzlin et al.,
1989). Serum osteocalcin is the most abundant noncolla-
genous protein of bone matrix. It is synthesised by the
osteoblasts and circulates in blood. Pyridinolines are derived
from three hydroxylysine or lysine residues in collagens and
form a cross-link between polypeptide chains in collagen
fibres of bone, cartilage and tendon; thus they are not an
absolute measure of bone collagen breakdown. The existing
methods for the determination of pyridinoline cross-links are
tedious and impractical outside of a clinical research labora-
tory. In addition, assays based on urine samples are assoc-
iated with several sources of error.
Our studies have aimed at simultaneous determination of
bone formation and resorption in serum specimens. The
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major collagen in bone is type I collagen, which is syn-
thesised by osteoblasts and accounts for about 90% of the
organic matrix (Simon et al., 1984; Melkko et al., 1990). This
collagen is formed as a large precursor protein, type I procol-
lagen. Assay of the carboxyterminal propeptide of type I
procollagen (PICP) is a test with which it is possible to
follow the synthesis of type I collagen (Melkko et al., 1990).
In addition, we have recently developed a bone resorption
assay which is based on cross-linked peptide liberated during
type I collagen degradation (ICTP).
The purpose of this preliminary study was to find out
whether these novel immunoassays of type I collagen meta-
bolites are useful as indices of bone turnover for predicting
prognosis and evaluating treatment response in multiple mye-
loma.
Patients
Fifteen consecutive patients (six females and nine males,
mean age 59 years, range 33-80 years) with untreated multi-
ple myeloma were prospectively studied with respect to col-
lagen turnover. The diagnosis was based on the detection of
an M-component in serum or urine and of abnormal plasma
cells in bone marrow biopsy or on the histological diagnosis
ofplasmacytoma from a skeletal tumour. The clinical staging
system of Durie and Salmon (1975) was applied. Clinical
characteristics of the patients are given in Table I. All
patients had widespread focal skeletal disease, evident in
roentgenograms. In addition, ten of them had vertebral
osteoporosis. The levels of serum calcium and transaminases
were normal. Only one patient had an increased serum crea-
tinine concentration (180,mol 1') at the start of therapy.
The patients were treated with melphalan (9-12 mg m-2) and
prednisolon (1 mg kg-') during four consecutive days every
fourth week. At the beginning three patients were operated
because of a pathological fracture and 14 patients received
irradiation. Radiotherapy was given also later to painful
bone lesions or impeding fracture. The follow-up time varied
from 4 to 37 months.
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Table I Clinical details and pretreatment laboratory values of 15 patients with multiple myeloma
Clinical S-AP S-ICTP S-PICP Bone Treatment Follow-up
Patient Age/sex Paraprotein stage U-Ca/Cr U-OHP/Cr Ul-1 .g 1h' l tg 1' lesions RT OPE response months
1 63 M IgG-lambda II a 0.07 22 176 3.6 94 2 (6) + - Responder 11 a
2 74 F IgA-kappa II a 0.44 14 167 8.8 181 1 + 2 (6) + + Responder 35 a
3 57 M IgG-lambda II a 0.27 10 200 2.6 65 2 (4) + - Responder 32 a
4 71 M IgA-kappa 11 a 0.49 6 121 2.1 56 2 (5) - - Responder 26 a
5 56 M IgG-lambda II a 0.90 9 168 3.3 79 2 (6) + - Responder 11 a
6 57 M IgG-kappa II a 0.60 13 129 2.6 69 2 (5) + - Responder 37 a
7 33 M B-J-lambda II a 0.50 50 182 4.3 119 1 + 2 (5) + - Responder 8 a
8 45 M IgG-lambda II a 0.28 17 127 4.3 100 1 + 2 (5) + - Recurrence 31 a
9 67 F B-J-lambda II a 0.57 13 238 7.2 112 1 + 2 (6) + + Recurrence 37 d
10 63 F IgA-lambda II a 0.15 4 394 5.8 114 1 + 2 (9) + - Recurrence 25 d
11 51 F IgA-kappa III a 0.51 79 252 4.3 142 1 + 3 (12) + - Recurrence 22 d
12 55 M IgG-kappa III a 0.88 259 128 16.4 137 1 + 3 (28) + - Nonresponder 10 d
13 80 F IgA-kappa III a 0.80 90 275 7.9 205 1 + 3 (38) + + Nonresponder 4 d
14 66 M IgA-kappa III a 0.62 122 173 13.3 128 1 + 3 (21) + - Nonresponder 10 d
15 46 F B-J-kappa III a 0.93 17 159 28.9 80 1 + 3 (21) + - Nonresponder 4 d
Bone lesions are determined as follows: 1 = osteoporisis, 2 = lesions < 10; 3 = lesions > 10 and/or extensive bone destruction (the number of
parenthesis indicate measureable lesions). M = male, F = female; RT = radiotherapy; OPE = operation; a = alive; d = dead. References intervals:
Ca/Cr, 0.15-0.34mmolmmolP'; OHP/Cr, 20-42 1molmmol-'; AP, 60-275 U 1-'; ICTP, 1.5-4.0tLg1'; PICP, 50-200JLgl-'.
Methods
The effect of treatment was followed by determinating serum
and urinary M protein, fasting urinary calcium/creatinine
(Ca/Cr) and hydroxyproline/creatinine (OHP/Cr) ratios as
well as serum calcium, creatinine, alkaline phosphatase (AP)
and transaminase concentrations (Elomaa et al., 1983). The
samples for serum PICP and ICTP, together with those for
the other determinations, were collected one day before start-
ing each treatment course, since corticosteroids have a nega-
tive effect on bone collagen formation. Serum samples for
PICP and ICTP were stored at -20°C until analysed. The
whole skeleton was investigated with X-rays every 6 months
and additionally when needed. The bone lesions were scored
as follows: osteoporosis = score 1, < 10 lytic lesions = score
2 and > 10 lytic lesions or extensive skeletal destruction =-
score 3.
Radioimmunoassaysfor type I collagen metabolites
The radioimmunoassay for analysing the concentration of
the carboxyterminal propeptide of type I procollagen (PICP)
has been established by isolating type I procollagen from the
medium of primary cultures of human skin fibroblasts and
by digesting it with highly purified bacterial collagenase to
liberate PICP (Melkko et al., 1990). The concentration of
PICP was measured in duplicate 100llI serum samples with
an equilibrium radioimmunoassay, obtained from Orion
Diagnostica (SF-90460 Oulunsalo, Finland). The sensitivity
of the test was 1.2 tLg [-'. The intra-assay coefficient of varia-
tion is around 3%. The corresponding interassay variation is
around 5%. The reference interval (mean ± 2 s.d.) for women
(18-61 years of age) is 50-1701agl-', with no apparent
correlation with age and for men (18-61 years) 50-200
,.gl-', with an inverse correlation with age (Melkko et al.,
1990). The serum PICP antigen is stable upon repeated freez-
ing and thawing and for several years of storage at - 20°C
(Melkko et al., 1990).
The carboxyterminal, pyridinoline-cross-linked telopeptide
(ICTP) parts of type I collagen were liberated from decalci-
fied human femoral bone, removed during hip surgery, by
digesting with bacterial collagenase or trypsin. The cross-
linked peptide was purified by two successive reverse-phase
separations on HPLC and its identity verified by N-terminal
amino acid sequencing. Polyclonal antibodies against the
telopeptide region were produced in rabbits and the peptide
labelled with the chloramine T-method. In a radioimmuno-
assay serum samples give inhibition curves parallel with the
standard antigen, indicating that during normal bone turn-
over a similar fragment is set free and remains immuno-
chemically intact. In gel filtration analysis of serum only one
peak of low molecular weight is found. An equilibrium type
of immunoassay was developed using 100 jil samples and
taking 4 h to perform (Risteli et al., 1991). The reference
interval of ICTP in normal human serum (n = 44) was found
to vary between 1.5 and 4.0 tg I-'. A commercial version of
the assay is available from Orion Diagnostica, SF-90460
Oulunsalo, Finland. The intra- and interassay coefficients of
variation of the method are around 5 and 7%, respectively.
The serum ICTP antigen is stable during storage at -20°C
for several years (unpublished data).
Statistical analysis
The usual linear correlation coefficents were calculated
between the different markers. Correlations between the
markers and the number of focal bone lesions were evaluated
using a method of all possible subsets regression (the lowest
Mallows' Cp for the best subset) (Drapor & Smith, 1981).
The relationship of the markers with survival (Kaplan-Mayer
product limit estimator) was analysed by the Cox propor-
tional hazards regression model (Drapor & Smith, 1981).
Because collagen metabolites were log-normally distributed,
similarly to AP, OHP/Cr and Ca/Cr, the variables were
log-transformed before the calculations. The analyses were
performed using the BMDP-PC90 programme (Statistical
Software inc., Los Angeles, CA).
Results
The patients were grouped according to their response to the
therapy (Durie & Salmon, 1975). Those with a reduction by
more than 50% in the concentration of the M protein in
serum or in urine were defined as responders. If this was not
achieved during 6 months and the osteolytic lesions increased
in size or new bone lesions appeared, the therapy was con-
sidered to have failed (nonresponders). Using these criteria
11 patients were responders, four of which, however, later
developed a recurrence, and four patients were nonrespon-
ders. The median survival of the patients was 30 months.
Responders
The fasting urinary Ca/Cr ratio was elevated in five out of
the seven patients at the beginning of the treatment, but
decreased to the reference interval in all of them. The fasting
urinary OHP/Cr ratio was low in all except one of the
patients and remained low during the treatment. Every
patients had a normal serum AP activity (Table I). The initial
serum PICP values were within the reference range in all
patients (Figure 1). The serum concentration of ICTP was
about the reference interval in two patients, whose values











Figure 1 The concentrations of PICP and ICTP in serum during
treatment in responders. The area between the dotted lines
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Figure 2 The concentrations of PICP and ICTP (log-scale) in
serum during treatment in patients with an initial remission and a
later recurrence. The filled symbols present the values at the time
of renal failure. The area between the dotted lines indicates the
reference interval.
Patients with recurrence
Four patients first responded to the therapy with a decrease
in the concentration of M protein. Before treatment, the
urinary Ca/Cr was elevated in two of these patients, urinary
OHP/Cr and serum AP only in one patient. The pretreatment
level of ICTP was elevated in every patients, whereas the
PICP concentration was within the reference range (Table I,
Figure 2). At the time of recurrence (at 12, 18, 24 and 30
months, respectively), the bone lesions were found to pro-
gress, and the M protein and ICTP concentrations increased.
PICP was above the upper limit of the reference interval in
only one patient. Three patients died, having hypercalcaemia
in the terminal phase. In one of them renal function was
impaired (creatinine 182jimol 1', calcium 3.93 mmol I' and
ICTP 17.9 ,ig l-') but could be restored again by hydration
and calcitonin infusions (creatinine 119 jmoll1', calcium
2.14 mmol 1' and ICTP 90.5 lig 1-1).
Nonresponders
In all four patients bone disease progressed leading to death.
Two patients developed hypercalcaemia; renal function
worsened in both of them. The fasting urinary Ca/Cr ratio
was increased at the beginning of treatment in all these
patients. The fasting OHP/Cr ratio was elevated in three
patients and the serum AP activity was normal (Table I). The
serum PICP concentrations were within the normal range,
whereas the serum ICTP levels were high (Table I, Figure 3).
The highest ICTP values were seen in the patients with
hypercalcaemia and renal failure (ICTP 43.3 jig -', calcium
2.87 mmol 11, creatinine 159jimol I` and ICTP 33.5jig 1-',
calcium 2.69 mmol-1, creatinine 661 jimol- 1', respectively).
Correlations andregressions
No positive correlation was found between the concentra-
tions of ICTP and PICP either before or during the treat-
ment. When the pretreatment levels of different markers,
including that of the M protein, were correlated with the
number of bone lesions, there was a positive relationship
between bone lesions and ICTP (r = 0.58; P = 0.02) and
between bone lesions and OHP/Cr (r = 0.55; P = 0.03).
When the method of all possible subset regression was used
to explain the number of bone lesions by the markers, the
most significant marker seemed to be ICTP (Cp= 4.1; R2 =
34%). The best two marker subset (Cp = 1.5; F = 7.06, P =
0.0094) was ICTP (t = 2.9; P = 0.01) and M-protein (t = 2.3;
P = 0.04). This model explained 54% of the variance of the
lesions. Of all the markers, ICTP was the only statistically
significant predictor for survival (coeff/SE = 2.1; P<0.05).
Discussion
Remodelling of bone first comprises a phase of osteoclast
activation and osteoclastic bone resorption with the forma-
tion of a resorption cavity. Subsequently, osteoblasts syn-
thesis type I collagen. Then the osteoid matrix thus formed
undergoes mineralisation and self-repair of skeletal tissue
occurs. In myeloma, the amount of bone deposited in a
resorption cavity does not equal that removed (Kanis et al.,
1988). As a result, excessive bone resorption occurs, leading
to a disproportionally increased concentration of ICTP,













Figure 3 The concentrations of PICP and ICTP in serum during
treatment in nonresponders. The filled symbols present the values
at the time of renal failure. The area between the dotted lines
indicates the reference interval.
during type I collagen degradation. In this study, the ICTP
concentration correlated with the number of osteolytic
lesions as well as did the OHP/Cr ratio. ICTP was also
superior to M protein, when these markers were correlated
with survival. It is known that production of the M compo-
nent predicts the stage of the disease with resonable accuracy,
but as a single parameter it does not predict survival (Durie
& Salmon, 1975). This is explained by the fact that a high M
component level can be due to either a small number of cells
producing large quantities of the M component per cell or a
large number of cells producing only a small amount of the
M component per cell.
In our patients ICTP behaved like a tumour marker:
elevated levels indicated a progressive or recurring disease,
whereas decreasing levels were associated with a regressive
disease. The ICTP concentration observed before treatment
was high in the patients who later turned out to be nonre-
sponders or who got a relapse after an initial remission.
Thus, an initially high ICTP value seems to predict the
prognosis in the patients who fail to respond to the treat-
ment. Finding an elevated ICTP concentration could thus
allow clinicians to use more aggressive chemotherapy or to
combine other drugs to the treatment, such as bisphos-
phonates, which inhibit osteoclastic bone resorption (Elomaa
et al., 1983; Merlini et al., 1990). Since the number of
patients in the present study is small, we will test the validity
of this conclusion in a much larger group of patients, par-
ticipating in a randomised study on the effect of clodronate,
combined with the ordinary treatment with melphalan and
prednisolon.
Before interpreting changes in serum ICTP concentration,
one should remember that ICTP is cleared by kidney and
renal failure may influence the values. Nevertheless, after
restoration of renal function we noted the highest ICTP
value which increased simultaneously with progressive osteo-
lysis. We have not seen high ICTP levels without excessive
bone resorption. On the other hand, we have no experience
of ICTP values in patients who have acute renal failure
without bone disease. Using the methods of calcium kinetics
and dynamic histomorphometry, we have shown a significant
correlation between serum ICTP concentration and bone
resorption in patients with low and high bone turnover rates
(Eriksen et al., 1992).
The lack of correlation between ICTP and PICP indicates
unbalanced bone turnover and suggests unchanged or even
depressed bone formation in multiple myeloma. This is in
accordance with clinical experience, since in myeloma the
osteolytic holes rarely heal during chemotherapy. Cortico-
steroids are known to inhibit osteoblast activity and collagen
synthesis (Lykert & Raisz, 1990; Canalis, 1983; Nielsen et al.,
1988). Because the samples here were taken before each
treatment course, the low or normal levels of serum PICP in
myeloma patients indicate an inhibition of osteoblast func-
tion by the disease rather than the effect of corticosteroids.
Indeed, it has been recently shown that the concentration of
osteocalcin in serum correlates inversely with the severity of
multiple myeloma, the lowest values being observed in
patients with extensive lytic lesions with frequent hypercal-
caemia (Bataille et al., 1990).
Urinary hydroxyproline excretion is strongly affected by
dietary collagen; in principle this is also possible for the
urinary pyridinoline cross-links, although they do not appear
to be absorbed after gelatin load (Colwell et al., 1990). PICP,
on the other hand, is a large (Mr 100,000) globular protein
released from type I procollagen during the extracellular
phase of collagen biosynthesis. The serum ICTP antigen is a
composite of three cross-linked peptides, have a Mr of more
than 9,000, and released by proteolytic digestion of type I
collagen fibres during bone resorption. PICP and ICTP are
thus too large to be absorbed in antigenically intact form
from the diet.
Another advantage of ICTP as a marker of bone resorp-
tion over hydroxyproline or the pyridinoline cross-links is the
fact that ICTP still carries information about the collagen
type it originates from. Hydroxyproline is present in all
collagenous proteins and in some other proteins, e.g. the Clq
component of complement. The pyridinoline cross-links are
more selective, as they are formed during the maturation of
collagen fibres in bone and cartilage, e.g. in the collagen
types I and II. Although type I collagen is also found in large
quantities in soft tissues, the structure of its mature cross-
links e.g. in skin differs from that in bone (Mechanic et al.,
1987). Thus it is likely that skin collagen degradation does
not lead to liberation of antigens reacting in the ICTP assay.
However, this question warrants further study.
In conclusion, the concentration of the cross-linked car-
boxyterminal telopeptide of type I collagen (ICTP) is a sen-
sitive and specific bone resorption marker, which strongly
correlates with the number of bone lesions and the survival
in multiple myeloma. In contrast to ICTP, the concentration
of PICP, which is derived from type I collagen synthesis, is
relatively low, suggesting unchanged or even depressed bone
formation. Simultaneous use of these serum markers of type
I collagen metabolism offers an additional and easy means to
follow bone turnover and evaluate the response to therapy in
multiple myeloma.
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